S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:CALT

Calliditas Therapeutics AB (publ) - CALT Stock Forecast, Price & News

$22.40
-0.72 (-3.11%)
(As of 03/28/2023 03:59 PM ET)
Add
Compare
Today's Range
$21.92
▼
$23.00
50-Day Range
$16.80
▼
$25.24
52-Week Range
$10.82
▼
$25.49
Volume
13,687 shs
Average Volume
14,859 shs
Market Capitalization
$667.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.00

Calliditas Therapeutics AB (publ) MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
249.9% Upside
$79.00 Price Target
Short Interest
Healthy
0.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Calliditas Therapeutics AB (publ) in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to $4.42 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

688th out of 1,002 stocks

Pharmaceutical Preparations Industry

338th out of 488 stocks

See Top Rated MarketRank™ Stocks Here

CALT stock logo

About Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

March 24, 2023 | americanbankingnews.com
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $24.10
March 22, 2023 | americanbankingnews.com
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Unusually-High Trading Volume
March 28, 2023 | Weiss Ratings (Ad)
Banking Nightmare
During and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …
March 19, 2023 | finance.yahoo.com
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
March 16, 2023 | barrons.com
Calliditas Therapeutics AB ADR
March 13, 2023 | msn.com
Calliditas jumps 35% on prospects for full approval of kidney disease therapy
March 3, 2023 | benzinga.com
Calliditas Therapeutics Stock (NASDAQ:CALT), Guidance and Forecast
March 1, 2023 | finance.yahoo.com
Analyst Sits On Fence While Initiating Calliditas Citing 'Near-Term Opportunity But Longer-Term Questions'
March 28, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
March 1, 2023 | seekingalpha.com
Calliditas: Underfollowed Swedish Biotech Focusing On Rare Kidney Disease
February 24, 2023 | msn.com
Calliditas Therapeutics reports Q4 results
February 23, 2023 | finance.yahoo.com
Calliditas - Year-End Report, 2022
February 2, 2023 | benzinga.com
First Alberta Clinical Site for Study of Psychedelic-Assisted Treatment for Alcohol Use Disorder Approved
February 2, 2023 | finance.yahoo.com
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
January 25, 2023 | seekingalpha.com
Pliant Therapeutics begins $175M public offering; closes up 35%
January 6, 2023 | seekingalpha.com
Chinook Therapeutics: Best Biotech For Kidney Disease Exposure, With Catalysts
December 21, 2022 | finance.yahoo.com
Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2019/2022
December 13, 2022 | finance.yahoo.com
Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
November 15, 2022 | finanznachrichten.de
Calliditas Therapeutics: Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA
November 15, 2022 | finance.yahoo.com
Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA
November 14, 2022 | finance.yahoo.com
Calliditas Therapeutics: Interim Report Q3, 2022
November 7, 2022 | finanznachrichten.de
Calliditas Therapeutics: Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape
October 21, 2022 | finance.yahoo.com
Calliditas Therapeutics' nomination committee composition for the AGM 2023
October 19, 2022 | finance.yahoo.com
Kidney International Publishes Results from NefIgArd Phase 3 Trial Evaluating TARPEYO® (budesonide) in IgA Nephropathy
October 6, 2022 | benzinga.com
XTORTX Therapeutics shares are trading lower after the company announced a $5 million public offering.
September 20, 2022 | finance.yahoo.com
Calliditas' partner STADA launches the first medicine authorized in the EU for treating primary IgA nephropathy
August 19, 2022 | seekingalpha.com
Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
See More Headlines
Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Company Calendar

Last Earnings
11/17/2021
Today
3/28/2023
Next Earnings (Estimated)
5/17/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALT
CUSIP
N/A
CIK
1795579
Web
www.calliditas.se
Phone
46-0-841-130-05
Fax
N/A
Employees
66
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$79.00
Low Stock Price Forecast
$79.00
Forecasted Upside/Downside
+249.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,860,000.00
Net Margins
-56.10%
Pretax Margin
-50.99%
Return on Equity
-55.18%
Return on Assets
-27.29%

Debt

Debt-to-Equity Ratio
0.95
Current Ratio
4.34
Quick Ratio
4.33

Sales & Book Value

Annual Sales
$79.63 million
Price / Sales
8.45
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.55 per share
Price / Book
8.85

Miscellaneous

Outstanding Shares
29,790,000
Free Float
29,131,000
Market Cap
$672.66 million
Optionable
Not Optionable
Beta
1.48

Social Links


Key Executives

  • Ms. Renee Aguiar-Lucander (Age 60)
    Chief Exec. Officer
  • Mr. Fredrik Johansson (Age 45)
    Chief Financial Officer
  • Dr. Katayoun Welin-Berger Ph.D. (Age 54)
    VP of Operations
  • Dr. Johan Haggblad Ph.D. (Age 64)
    Chief Scientific Officer
  • Mr. Mikael Widell (Age 64)
    Head of Communications & IR
  • Mr. Jonathan A. Schur (Age 69)
    Group Gen. Counsel
  • Ms. Sandra Frithiof
    Head of HR
  • Ms. Ann-Kristin Myde BSc (Age 67)
    Head of Clinical Devel. & VP of Project Management
  • Mr. Andrew B. Udell B.Sc. (Age 52)
    M.B.A., Pres of North America Commercial
  • Dr. Krassimir Mitchev (Age 63)
    Head of Medical Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













CALT Stock - Frequently Asked Questions

Should I buy or sell Calliditas Therapeutics AB (publ) stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CALT shares.
View CALT analyst ratings or view top-rated stocks.

What is Calliditas Therapeutics AB (publ)'s stock price forecast for 2023?

4 brokerages have issued twelve-month price objectives for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price forecasts range from $79.00 to $79.00. On average, they expect the company's stock price to reach $79.00 in the next twelve months. This suggests a possible upside of 249.9% from the stock's current price.
View analysts price targets for CALT or view top-rated stocks among Wall Street analysts.

How have CALT shares performed in 2023?

Calliditas Therapeutics AB (publ)'s stock was trading at $17.00 at the start of the year. Since then, CALT stock has increased by 32.8% and is now trading at $22.58.
View the best growth stocks for 2023 here.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 22,700 shares, an increase of 58.7% from the February 28th total of 14,300 shares. Based on an average trading volume of 14,300 shares, the short-interest ratio is presently 1.6 days.
View Calliditas Therapeutics AB (publ)'s Short Interest.

When is Calliditas Therapeutics AB (publ)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 17th 2023.
View our CALT earnings forecast.

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings results on Wednesday, November, 17th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.62. The company earned $22.92 million during the quarter. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 55.18% and a negative net margin of 56.10%. During the same period in the prior year, the business earned ($0.62) earnings per share.

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

Who are Calliditas Therapeutics AB (publ)'s major shareholders?

Calliditas Therapeutics AB (publ)'s stock is owned by many different retail and institutional investors. Top institutional investors include HBK Sorce Advisory LLC (0.30%), Ironwood Investment Management LLC (0.09%), Optiver Holding B.V. (0.04%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $22.58.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has a market capitalization of $672.66 million and generates $79.63 million in revenue each year. The company earns $-40,860,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The official website for the company is www.calliditas.se. The company can be reached via phone at 46-0-841-130-05 or via email at mikael.widell@calliditas.com.

This page (NASDAQ:CALT) was last updated on 3/28/2023 by MarketBeat.com Staff